Aptevo Therapeutics (APVO) Non-Current Debt (2016 - 2022)
Aptevo Therapeutics (APVO) posted Non-Current Debt of $1.5 million for Q4 2022, down 23.77% sequentially from $1.9 million in Q3 2022, and down 60.72% YoY from $3.7 million in Q4 2021.
Aptevo Therapeutics (APVO) Non-Current Debt (2016 - 2022) Analysis & Trends
Aptevo Therapeutics has reported Non-Current Debt for 7 years, with the latest figure at $1.5 million in Q4 2022.
- Quarterly Non-Current Debt fell 60.72% year-over-year to $1.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.5 million (down 60.72% YoY) and the FY2022 annual result came in at $1.5 million, down 60.72% from the prior year.
- Non-Current Debt fell to $1.5 million in Q4 2022 per APVO's latest filing, from $1.9 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $25.2 million in Q3 2020 and troughed at $1.5 million in Q4 2022.
- A 5-year average of $11.1 million and a median of $9.3 million in 2018 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2019 and 2021: Non-Current Debt surged 38.93% in 2019, then tumbled 84.08% in 2021.
- Over 5 years, Non-Current Debt stood at $19.3 million in 2018, then grew by 1.45% to $19.6 million in 2019, then advanced by 2.54% to $20.1 million in 2020, then plunged by 81.51% to $3.7 million in 2021, then tumbled by 60.72% to $1.5 million in 2022.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.5 million, $1.9 million, and $2.4 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 8.96 Bn |
| 10 | Aptevo Therapeutics | 3.16 Mn | -6.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.36 Mn |
| Mar 31, 2022 | 2.80 Mn |
| Dec 31, 2021 | 3.71 Mn |
| Sep 30, 2021 | 4.01 Mn |
| Jun 30, 2021 | 4.32 Mn |
| Mar 31, 2021 | 4.61 Mn |
| Dec 31, 2020 | 20.05 Mn |
| Sep 30, 2020 | 25.20 Mn |
| Jun 30, 2019 | 19.56 Mn |
| Mar 31, 2019 | 19.42 Mn |
| Dec 31, 2018 | 19.28 Mn |
| Sep 30, 2018 | 19.14 Mn |
| Jun 30, 2018 | 15.40 Mn |
| Mar 31, 2018 | 13.98 Mn |
| Dec 31, 2017 | 15.73 Mn |
| Sep 30, 2017 | 17.48 Mn |
| Jun 30, 2017 | 18.75 Mn |
| Mar 31, 2017 | 18.44 Mn |